Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen

View the summary and implementation tools

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta255

1 Guidance

1.1 Cabazitaxel in combination with prednisone or prednisolone is not recommended for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

1.2 People currently receiving cabazitaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen should have the option to continue treatment until they and their clinicians consider it appropriate to stop.